维思通与卓菲治疗精神分裂症的临床对照分析  

Clinical control study of Weisitong and Zhuofei on schizophrenia

作　　者：罗来兴[1] 

机构地区：[1]惠州市第二人民医院,广东惠州516001

出　　处：《中国医药导报》2009年第21期62-63,共2页China Medical Herald

摘　　要：目的:通过分析合资维思通与国产卓菲治疗精神分裂症的临床效果,根据家境和个体情况选取药物。方法:将70例精神分裂症患者随机分为两组,经8周治疗,以CCMD-3精神分裂症的诊断标准、PANSS评定疗效,TESS评定副作用。结果:两组治疗后PANSS评分与治疗前比较,均有显著性差异;治疗后随治疗时间延长而下降,副作用少,说明两药治疗精神分裂症效果显著。结论:维思通疗效比卓菲好,起效快;不良反应卓菲比维思通高;但两者的疗效和副作用比较均无显著性差异,而价格有差别。临床可根据患者经济状况和个体差异来选择使用。Objective： To discuss the clinical effect of joint-stock Risperidone （Weisitong） and domestic Risperidone （Zhuofei） on schizophrenia. The choosing of the two medicaments was based on the family financial situation and individual difference. Methods： 70 patients with schizophrenia were randomly divided into two groups, after 8 weeks of treatment, all the patients were selected in accordance with the CCMD-3 diagnosis standard. The clinical effect of patients were measured by the PANSS and the side effects were evaluated with the TESS. Results： There was significant differences on PANSS between pre- treatment and post-treatment. The score declines and the side effect decreased with the prolonging of time. This showed that the two medicaments had evident clinic efficacy on schizophrenia. Conclusion： Joint-stock Risperidone show better effect and faster effect than domestic Risperidone, but the side effects by contraries. There is not significant differences on curative effect and side effect, but the price show difference. So we can choose anyone according to the economy status and individual difference.

关 键 词：精神分裂症 维思通 卓菲 疗效 

分 类 号：R749.3[医药卫生—神经病学与精神病学]